Sermorelin Acetate: PK, Diagnostic History & Stability Notes

Sermorelin acetate is the acetate salt of the 29-residue N-terminal fragment of human growth hormone-releasing hormone, commonly written GHRH(1-29)NH2 (sequence YADAIFTNSYRKVLGQLSARKLLQDIMS-NH2; CAS 86168-78-7; free-base molecular weight near 3,357.9 Da). It binds the pituitary GHRH receptor (GHRHR) and stimulates pulsatile endogenous growth hormone (GH) secretion. Peer-reviewed reviews describe it as the shortest synthetic peptide that retains full GHRH biological activity. This guide focuses on pharmacokinetics, the historical diagnostic-test record, solution stability, and laboratory handling; the catalog material is prepared for research purposes only and is not approved for human or veterinary therapy, diagnosis, or disease treatment.

Identity and Regulatory Background

Sermorelin’s molecular identity is fixed: the native 1-29 sequence without the receptor-modifying substitutions used in later analogs, supplied as an acetate salt. Published clinical reviews document its long history as a diagnostic GH stimulation agent and as a pediatric endocrinology compound [1]. Secondary pharmaceutical references note that the branded product Geref was approved by the U.S. FDA in 1997 for diagnostic evaluation of pituitary GH secretory capacity and idiopathic GH deficiency in children, then discontinued commercially in 2008 for commercial rather than stated safety reasons; those references should be verified against FDA records before citation in any formal document. A current research-grade catalog vial is not equivalent to any withdrawn pharmaceutical formulation.

Mechanism and Pharmacokinetics

Like other GHRH analogs, sermorelin activates GHRHR through Gs-cAMP signaling, driving both acute GH granule release and GH synthesis support. The decisive pharmacokinetic feature is its brevity. Native GHRH circulates only on the order of minutes and is rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) at the Tyr1-Ala2 N-terminal bond, with endopeptidases contributing further clearance [2]. Sermorelin, being the native sequence, shares that susceptibility; endocrine reviews describe intravenous GH pulses peaking within tens of minutes and returning to baseline over roughly an hour [2]. Short exposure favors diagnostic challenge designs rather than steady-state maintenance models.

Published Diagnostic Record

A peer-reviewed review of sermorelin’s use in children with idiopathic GH deficiency summarizes that intravenous or subcutaneous sermorelin specifically stimulates anterior-pituitary GH release, and that an intravenous dose near 1 µg/kg body weight was used as a relatively specific diagnostic GH-response test [1]. The review also cautions that GH responses can be affected by confounders such as obesity, undernutrition, and other endocrine states, so a challenge test must be interpreted within a full clinical context rather than from a single value [1]. That nuance transfers directly to research design: define sampling windows, use assay-validated GH and IGF-1 measurements, and include vehicle or comparator arms in any preclinical model.

Solution Stability and Reconstitution Notes

Product-level analytical documentation lists white lyophilized powder, solubility in water, saline, or dilute acetic acid, ≥98% HPLC purity, acetate content within stated limits, water content by Karl Fischer, and frozen storage away from light [3]. Because DPP-IV and serum proteases remain active in aqueous media, reconstituted solution stability should follow the batch CoA rather than generic assumptions; product handling notes commonly recommend refrigerated use within days, aliquoted frozen stock for longer storage, avoidance of repeated freeze-thaw cycles, and gentle mixing without vortexing. For cell-culture work, filter-sterilize through a 0.22 µm filter and refresh culture medium on a schedule matched to the assay’s proteolytic environment.

Research Protocol and Assay Considerations

Published numerical doses from diagnostic or pediatric studies belong to those protocols and are not a recommendation for a research user. Practical protocol choices include: challenge-style serial GH sampling over the first hour; IGF-1 measured at longer intervals; cortisol and prolactin panels to characterize off-target endocrine signals; and side-by-side comparison with modified analogs such as Ipamorelin or GHRHR-modified peptides when the question concerns degradation resistance. QC review should cover sequence identity, intact mass, HPLC purity, net peptide content versus powder mass, acetate content, endotoxin, residual solvents, and a traceable signed certificate of analysis.

Safety and Evidence Boundaries

Reported acute observations across sermorelin challenge studies include injection-site reactions, flushing, and transient head symptoms; chronic-use evidence for a research-grade material is not established. The compound acts upstream of endogenous GH secretion rather than replacing GH, and feedback regulation remains part of the model. All experiments require institutional biosafety and ethics oversight; the material is not for self-administration, anti-doping rules prohibit secretagogue use in sport, and no disease-treatment claim may be derived from the catalog page.

Frequently Asked Questions

Q1: What peptide fragment is sermorelin?

It is GHRH(1-29)NH2, the 29-residue N-terminal fragment of native human GHRH; CAS 86168-78-7 [1][3].

Q2: Why is its half-life short?

The native Tyr-Ala N terminus is cleaved by DPP-IV and other proteases; endocrine reviews place native GHRH clearance in the minute range [2].

Q3: How was sermorelin used diagnostically?

Reviews describe IV challenge (near 1 µg/kg) as a GH-response stimulation test, with interpretation adjusted for confounders such as obesity and nutrition [1].

Q4: Is sermorelin the same as CJC-1295?

No. Sermorelin retains the native 1-29 sequence; CJC-1295 variants use cleavage-resistant substitutions, and the DAC version additionally carries an albumin-binding linker.

Q5: How should reconstituted solution be stored?

Follow the batch CoA; typical practice uses refrigerated short-term use, aliquoted frozen long-term storage, no repeated freeze-thaw cycles, and gentle mixing [3].

Q6: What QC documentation should be requested?

Sequence and intact-mass identity, HPLC purity, net peptide content, acetate content, endotoxin, residual solvents, and signed CoA traceability.

Q7: Can this material be used medically?

No. It is supplied for laboratory research only; the withdrawn branded pharmaceutical history does not make the current catalog item a medicine.

Research Material CTA

View the product entry: Sermorelin Acetate · related secretagogue: Ipamorelin Batch-level HPLC purity reporting, lab-tested CoA documentation, and worldwide tracked shipping for qualified research buyers. Research use only; verify current lot documentation before assay setup.

Sources

  1. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. https://pubmed-d.ncbi.nlm.nih.gov/18031173/
  2. Growth Hormone Doping in Sports: A Critical Review (Endocrine Reviews 33:155-186, 2012; native GHRH PK). https://academic.oup.com/edrv/article-pdf/33/2/155/8858256/edrv0155.pdf
  3. Product page identity and handling parameters (lot-specific CoA governs). https://hanpropeptides.com/product/sermorelin-acetate/

Related Research Guides


Leave a Reply

Your email address will not be published. Required fields are marked *